ES2605228T3 - Métodos para evaluar la capacidad de respuesta de un linfoma de células B al tratamiento con anticuerpos anti-CD40 - Google Patents
Métodos para evaluar la capacidad de respuesta de un linfoma de células B al tratamiento con anticuerpos anti-CD40 Download PDFInfo
- Publication number
- ES2605228T3 ES2605228T3 ES10715067.4T ES10715067T ES2605228T3 ES 2605228 T3 ES2605228 T3 ES 2605228T3 ES 10715067 T ES10715067 T ES 10715067T ES 2605228 T3 ES2605228 T3 ES 2605228T3
- Authority
- ES
- Spain
- Prior art keywords
- expression
- antibody
- sample
- seq
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17061509P | 2009-04-18 | 2009-04-18 | |
| US170615P | 2009-04-18 | ||
| PCT/US2010/031528 WO2010121231A1 (en) | 2009-04-18 | 2010-04-17 | Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2605228T3 true ES2605228T3 (es) | 2017-03-13 |
Family
ID=42358184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10715067.4T Active ES2605228T3 (es) | 2009-04-18 | 2010-04-17 | Métodos para evaluar la capacidad de respuesta de un linfoma de células B al tratamiento con anticuerpos anti-CD40 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9617600B2 (https=) |
| EP (1) | EP2419531B1 (https=) |
| JP (1) | JP5836929B2 (https=) |
| KR (1) | KR101787768B1 (https=) |
| CN (1) | CN102459639A (https=) |
| AU (1) | AU2010236168B2 (https=) |
| BR (1) | BRPI1011394A8 (https=) |
| CA (1) | CA2758523C (https=) |
| ES (1) | ES2605228T3 (https=) |
| IL (1) | IL215707A (https=) |
| MX (1) | MX2011010938A (https=) |
| WO (1) | WO2010121231A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101910414B (zh) | 2007-11-07 | 2016-01-13 | 健泰科生物技术公司 | 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物 |
| ES2709654T3 (es) | 2011-04-29 | 2019-04-17 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
| EP2568290B1 (en) | 2011-09-12 | 2017-02-22 | Atrys Health, SA | Methods for prognosis of diffuse large B-cell lymphoma |
| LT2882441T (lt) * | 2012-08-09 | 2020-07-27 | Celgene Corporation | Su imunitetu susijusių ir uždegiminių ligų gydymas |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| KR102270618B1 (ko) | 2012-10-30 | 2021-06-30 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| US10245266B2 (en) | 2014-05-19 | 2019-04-02 | Celgene Corporation | 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
| WO2017053555A1 (en) * | 2015-09-25 | 2017-03-30 | Celgene Corporation | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| WO2022120038A1 (en) * | 2020-12-02 | 2022-06-09 | Albert Einstein College Of Medicine | Method for predicting patient response to cd40-targeted therapies |
| CN117092336A (zh) * | 2023-06-16 | 2023-11-21 | 中国医学科学院北京协和医院 | 血浆n4bp1、creb1、ubap2、deaf1自身抗体标志物在弥漫大b细胞淋巴瘤预后预测中的应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5182368A (en) | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5874082A (en) | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
| ES2222463T3 (es) | 1993-12-23 | 2005-02-01 | Immunex Corporation | Uso de anticuerpos monoclonales o ligandos oligomericos solubles en la fabricacion de un medicamento para la prevencion o tratamiento de trastornos neoplasicos. |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| GB9425060D0 (en) | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| US6248535B1 (en) * | 1999-12-20 | 2001-06-19 | University Of Southern California | Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens |
| WO2001075166A2 (en) | 2000-03-31 | 2001-10-11 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| AU2001259215A1 (en) | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
| IL157946A0 (en) | 2001-04-02 | 2004-03-28 | Genentech Inc | Combination therapy |
| JP4025881B2 (ja) | 2001-04-27 | 2007-12-26 | キリンファーマ株式会社 | 抗ｃｄ４０モノクローナル抗体 |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| AU2004211955B2 (en) | 2003-02-06 | 2009-05-14 | Cedars-Sinai Medical Center | Gene expression markers for response to EGFR inhibitor drugs |
| US7767387B2 (en) | 2003-06-13 | 2010-08-03 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
| EP1664762A4 (en) | 2003-09-03 | 2008-08-13 | Us Gov Health & Human Serv | METHOD OF IDENTIFYING AND DIAGNOSIS OF, AND VIEWING, SURVIVAL IN LYMPHOMA |
| SI1682177T1 (sl) | 2003-11-04 | 2010-12-31 | Novartis Vaccines & Diagnostic | Uporaba antagonističnih anti-CD40 protiteles za zdravljenje kronične limfocitne levkemije |
| ATE447412T1 (de) | 2003-11-04 | 2009-11-15 | Novartis Vaccines & Diagnostic | Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren |
| ES2636470T3 (es) * | 2004-04-09 | 2017-10-05 | Genomic Health, Inc. | Marcadores de expresión génica para predecir la respuesta a la quimioterapia |
| JP5421590B2 (ja) * | 2005-05-18 | 2014-02-19 | ノバルティス アーゲー | 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法 |
| AU2006247067B2 (en) | 2005-05-18 | 2012-06-07 | Novartis Ag | Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling |
| US8303955B2 (en) * | 2005-05-26 | 2012-11-06 | Seattle Genetics, Inc. | Humanized anti-CD40 antibodies and their methods of use |
| ES2624863T3 (es) | 2005-06-08 | 2017-07-17 | Millennium Pharmaceuticals, Inc. | Métodos para identificación, evaluación, y tratamiento de pacientes con terapia de cáncer |
| JP2009508484A (ja) | 2005-09-16 | 2009-03-05 | バイオベイター・テクノロジーズ・アクチボラゲット | アレルゲン性タンパク質の同定のためのインビトロアッセイ |
| DE102005052384B4 (de) | 2005-10-31 | 2009-09-24 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Erkennung, Markierung und Behandlung von epithelialen Lungentumorzellen sowie Mittel zur Durchführung des Verfahrens |
| US20090304687A1 (en) | 2005-12-09 | 2009-12-10 | Seattle Genetics , Inc. | Methods of using cd40 binding agents |
| US7527774B2 (en) | 2005-12-22 | 2009-05-05 | Basf Catalysts Llc | Inlet metallic foam support coupled to precious metal catalyst for application on 4 stroke platforms |
| EP1987161A4 (en) * | 2006-01-20 | 2009-06-24 | Univ Mcgill | METHOD FOR IDENTIFYING CD40-SENSITIVE CELLS |
| WO2008079269A2 (en) | 2006-12-19 | 2008-07-03 | Genego, Inc. | Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom |
| CN101910414B (zh) * | 2007-11-07 | 2016-01-13 | 健泰科生物技术公司 | 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物 |
-
2010
- 2010-04-17 CN CN201080027267XA patent/CN102459639A/zh active Pending
- 2010-04-17 US US13/264,973 patent/US9617600B2/en active Active
- 2010-04-17 KR KR1020117027354A patent/KR101787768B1/ko active Active
- 2010-04-17 BR BRPI1011394A patent/BRPI1011394A8/pt active Search and Examination
- 2010-04-17 WO PCT/US2010/031528 patent/WO2010121231A1/en not_active Ceased
- 2010-04-17 ES ES10715067.4T patent/ES2605228T3/es active Active
- 2010-04-17 EP EP10715067.4A patent/EP2419531B1/en active Active
- 2010-04-17 AU AU2010236168A patent/AU2010236168B2/en not_active Ceased
- 2010-04-17 JP JP2012505990A patent/JP5836929B2/ja active Active
- 2010-04-17 CA CA2758523A patent/CA2758523C/en active Active
- 2010-04-17 MX MX2011010938A patent/MX2011010938A/es active IP Right Grant
-
2011
- 2011-10-11 IL IL215707A patent/IL215707A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010236168A1 (en) | 2011-11-10 |
| IL215707A0 (en) | 2012-01-31 |
| CA2758523C (en) | 2019-03-12 |
| US20120123695A1 (en) | 2012-05-17 |
| EP2419531A1 (en) | 2012-02-22 |
| CA2758523A1 (en) | 2010-10-21 |
| KR101787768B1 (ko) | 2017-10-18 |
| BRPI1011394A8 (pt) | 2018-06-26 |
| WO2010121231A1 (en) | 2010-10-21 |
| US9617600B2 (en) | 2017-04-11 |
| AU2010236168B2 (en) | 2015-08-13 |
| IL215707A (en) | 2016-08-31 |
| EP2419531B1 (en) | 2016-09-07 |
| CN102459639A (zh) | 2012-05-16 |
| JP5836929B2 (ja) | 2015-12-24 |
| JP2012523838A (ja) | 2012-10-11 |
| KR20120013992A (ko) | 2012-02-15 |
| MX2011010938A (es) | 2012-01-12 |
| BRPI1011394A2 (pt) | 2016-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2605228T3 (es) | Métodos para evaluar la capacidad de respuesta de un linfoma de células B al tratamiento con anticuerpos anti-CD40 | |
| Kallioniemi | Biochip technologies in cancer research | |
| ES2538504T3 (es) | Marcadores en la orina para la detección del cáncer de vejiga | |
| EP2154245B1 (en) | Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient | |
| ES2653851T3 (es) | Biomarcadores transcriptómicos para evaluación de riesgo individual en insuficiencia cardíaca de nueva aparición | |
| JP4435259B2 (ja) | 微量胃癌細胞の検出法 | |
| JP2005500834A (ja) | 敗血症または敗血症関連症候群の診断のためのバイオチップの使用 | |
| WO2002009573A2 (en) | Prognostic classification of endometrial cancer | |
| US9102706B2 (en) | Newly identified colon cancer marker and diagnostic kit using the same | |
| JP5031581B2 (ja) | Ａｍｌ、ｂ−ａｌｌおよびｔ−ａｌｌの診断用マーカー | |
| CN108474041A (zh) | 使用遗传标记的甲基化状态区分转移性-致死性前列腺癌与惰性前列腺癌 | |
| KR20120004286A (ko) | 림프종 진단 또는 예후 마커로서 Ｐｅｌｌｉｎｏ 1 | |
| KR101054952B1 (ko) | 간암 진단 및 환자 생존기간 예측용 마커인 ｕｑｃｒｈ, 그를 포함하는 키트 및 상기 마커를 이용한 간암 환자 생존기간 예측 | |
| CN116949168B (zh) | Cd73在帕金森病诊断中的应用 | |
| JP4317854B2 (ja) | 微量胃癌細胞の検出法 | |
| KR20110097498A (ko) | 전자파 노출을 진단하기 위한 마커 및 이를 포함하는 키트 | |
| EP2669384B1 (en) | Method for evaluating the presence of rheumatoid arthritis and biomarker set used in the same | |
| WO2006132983A2 (en) | Differential expression of molecules associated with vascular disease risk | |
| CN118957067B (zh) | 一种胸部肿瘤诊断标志物cpd及其相关诊断产品和应用 | |
| KR101069593B1 (ko) | 급성심근경색 진단용 마커 | |
| KR20110097497A (ko) | 전자파 노출을 진단하기 위한 마커 및 이를 포함하는 키트 | |
| KR20100086362A (ko) | 간암 진단 마커인 ａｐｏａ１, 그를 포함하는 키트 | |
| CN119193847A (zh) | Gsdmd在诊断胰腺癌中的应用 | |
| CN116875673A (zh) | 一种诊断心肌梗死的系统 | |
| KR101006226B1 (ko) | 간암을 진단하기 위한 마커인 ｃｘｃｌ２, 그를 포함하는키트 및 상기 마커를 이용한 간암 예측 방법 |